Alendronate and Urinary Tract Infection Risk
Fosamax (alendronate) is not listed in the drug label as a typical cause of urinary tract infection. [1] An observational study in patients undergoing lumbar fusion reported higher urinary tract infection rates in patients with osteoporosis (OR 1.18), but no causal relationship to alendronate specifically was established. [2]
Reported Adverse Reactions in the Fosamax Label
The Fosamax prescribing information describes clinically significant adverse reactions related to the gastrointestinal tract, mineral metabolism, musculoskeletal pain, osteonecrosis of the jaw, atypical fractures, and renal impairment, but urinary tract infection is not identified as a labeled adverse reaction. [1]
Evidence Linking Bisphosphonates/Osteoporosis to UTI
A retrospective matched cohort study found osteoporosis was associated with increased urinary tract infection rates after lumbar fusion (OR 1.18; 95% CI 1.08-1.29). [2] In that study, osteoporosis medications were not shown to significantly alter urinary tract infection risk for alendronate specifically based on the available abstract data. [2]
Clinical Interpretation
Urinary symptoms developing after starting Fosamax are more likely due to intercurrent factors rather than a recognized labeled adverse effect of the medication. [1] Urinary tract infection should be evaluated based on symptoms and diagnostic testing rather than attributed to alendronate without objective evidence. [1]
When Medical Evaluation Is Needed
Urgent evaluation is warranted for fever, flank pain, vomiting, pregnancy, immunocompromise, or inability to maintain oral intake, due to concern for complicated infection or pyelonephritis. [1]
Key Practical Points
Fosamax should not be discontinued solely for an uncomplicated suspected urinary tract infection without clinical evaluation of the cause. [1]